The first author of the publication, Dr Viktor Nabil Sayour, summarised the significance of the work below:
Heart failure patients have a significantly higher risk of new-onset cancer and cancer-associated mortality, compared to subjects free of heart failure. While both the prevention and treatment of new-onset heart failure in patients with cancer have been investigated extensively, there is less evidence about the prevention and treatment of new-onset cancer in patients with heart failure, and whether and how guideline-directed medical therapy should be modified when cancer is diagnosed in heart failure patients. The purpose of this review, written by a multinational board, is to elaborate and discuss the effects of pillar heart failure pharmacotherapies on cancer, and to identify areas for further research and novel therapeutic strategies to decrease cancer burden of heart failure.
The publication can be read by clicking on the following link: link
